The incidence of osteoporosis induced by glucocorticoid treatment is second only to that owing to oestrogen deficiency. Treatment and prevention of glucocorticoid-induced osteoporosis are, however, problematic. Can a new framework for the development of national guidelines help steer the diagnosis and management of glucocorticoid-induced osteoporosis towards calmer seas?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Bone remodeling serum markers in children with systemic lupus erythematosus
Pediatric Rheumatology Open Access 27 July 2022
-
Smad4 is required to inhibit osteoclastogenesis and maintain bone mass
Scientific Reports Open Access 12 October 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Grossman, J. M. et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 62, 1515–1526 (2010).
Lekamwasam, S. et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos. Int. http://dx.doi.org/10.1007/s00198-012-1958-1.
Adachi, J. D. et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 44, 202–211 (2001).
Weinstein, R. S., Jilka, R. L., Parfitt, A. M. & Manolagas, S. C. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J. Clin. Invest. 102, 274–282 (1998).
Kim, H. J. et al. Glucocorticoids suppress bone formation via the osteoclast. J. Clin. Invest. 116, 2152–2160 (2006).
Mazziotti, G., Angeli, A., Bilezikian, J. P., Canalis, E. & Giustina, A. Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol. Metab. 17, 144–149 (2006).
Xiong, J. et al. Matrix-embedded cells control osteoclast formation. Nat. Med. 17, 1235–1241 (2011).
Van Staa, T. P. et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 48, 3224–3229 (2003).
Teitelbaum, S. L., Seton, M. P. & Saag, K. G. Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis? Arthritis Rheum. 63, 325–328 (2011).
Saag, K. G. et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N. Engl. J. Med. 357, 2028–2039 (2007).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Teitelbaum, S. The conundrum of glucocorticoid-induced osteoporosis. Nat Rev Endocrinol 8, 451–452 (2012). https://doi.org/10.1038/nrendo.2012.89
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2012.89
This article is cited by
-
Bone remodeling serum markers in children with systemic lupus erythematosus
Pediatric Rheumatology (2022)
-
miR-27a promotes osteogenic differentiation in glucocorticoid-treated human bone marrow mesenchymal stem cells by targeting PI3K
Journal of Molecular Histology (2021)
-
Glucocorticoids, Inflammation and Bone
Calcified Tissue International (2018)
-
Smad4 is required to inhibit osteoclastogenesis and maintain bone mass
Scientific Reports (2016)
-
The cumulative incidence of and risk factors for latent beaking in patients with autoimmune diseases taking long-term glucocorticoids and bisphosphonates
Osteoporosis International (2016)